Search hospitals > New Jersey > Hackensack
Hackensack University Medical Center
Claim this profileHackensack, New Jersey 07601
Global Leader in Lymphoma
Global Leader in T-Lymphoblastic Leukemia/Lymphoma
Conducts research for Skin Cancer
Conducts research for Uterine Tumors
Conducts research for Cancer
982 reported clinical trials
52 medical researchers
Summary
Hackensack University Medical Center is a medical facility located in Hackensack, New Jersey. This center is recognized for care of Lymphoma, T-Lymphoblastic Leukemia/Lymphoma, Skin Cancer, Uterine Tumors, Cancer and other specialties. Hackensack University Medical Center is involved with conducting 982 clinical trials across 1,002 conditions. There are 52 research doctors associated with this hospital, such as Martin E Gutierrez, Katharine Offer, Burton E. Appel, and Derek Hanson, MD.Area of expertise
1Lymphoma
Global LeaderStage IV
Stage III
Stage II
2T-Lymphoblastic Leukemia/Lymphoma
Global LeaderStage II
CD19 positive
Philadelphia chromosome positive
Top PIs
Martin E GutierrezJohn Theurer Cancer Center at Hackensack University Medical Center3 years of reported clinical research
Expert in Solid Tumors
Expert in Uterine Tumors
48 reported clinical trials
85 drugs studied
Katharine OfferHackensack University Medical Center7 years of reported clinical research
Expert in Uterine Tumors
Expert in Osteosarcoma
35 reported clinical trials
67 drugs studied
Burton E. AppelHackensack University Medical Center5 years of reported clinical research
Studies Lymphoma
Studies T-Lymphoblastic Leukemia/Lymphoma
23 reported clinical trials
60 drugs studied
Derek Hanson, MDHackensack University Medical Center3 years of reported clinical research
Studies Cerebral Gliomas
Studies Brain Tumor
17 reported clinical trials
38 drugs studied
Clinical Trials running at Hackensack University Medical Center
Lymphoma
Breast Cancer
Prostate Cancer
Skin Cancer
Bladder Cancer
Brain Tumor
Multiple Myeloma
Uterine Tumors
Testicular cancer
Stroke
Long-term Ibrutinib
for Lymphoma
This trial aims to provide ongoing access to ibrutinib for patients who have benefited from it in previous studies. Ibrutinib is an oral medication that blocks a protein involved in cancer growth, helping to slow or stop the disease. The study will monitor safety and effectiveness over time. Ibrutinib has been studied extensively and is used to treat various B cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma.
Recruiting2 awards Phase 35 criteria
Levocarnitine
for Chemotherapy-Related Liver Protection in Leukemia and Lymphoma
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.
Recruiting2 awards Phase 3
Brentuximab Vedotin + Nivolumab
for Hodgkin's Lymphoma
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 positive lymphoma cells in a targeted way and delivers vedotin to kill them. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs such as doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine, and procarbazine hydrochloride work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Adding immunotherapy to the standard treatment of chemotherapy with or without radiation may increase survival and/or fewer short-term or long-term side effects in patients with classical Hodgkin lymphoma compared to the standard treatment alone.
Recruiting2 awards Phase 3
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Hackensack University Medical Center?
Hackensack University Medical Center is a medical facility located in Hackensack, New Jersey. This center is recognized for care of Lymphoma, T-Lymphoblastic Leukemia/Lymphoma, Skin Cancer, Uterine Tumors, Cancer and other specialties. Hackensack University Medical Center is involved with conducting 982 clinical trials across 1,002 conditions. There are 52 research doctors associated with this hospital, such as Martin E Gutierrez, Katharine Offer, Burton E. Appel, and Derek Hanson, MD.
Where is Hackensack University Medical Center located?
To reach Hackensack University Medical Center, located at 30 Prospect Avenue, Hackensack, New Jersey: Take I-80 West to NJ-17 South towards Paramus. Use the right two lanes to exit at 17A-17B for NJ-4 East towards Hackensack. Continue on NJ-4 East, then take the Prospect Avenue exit towards the hospital, which will be on your left.
Who should I call to ask about financial aid or insurance network?
For financial assistance, insurance, and billing inquiries at Hackensack University Medical Center, please call 888-568-3522. To request a copy of the Financial Assistance Policy and Application by mail, contact the Patient Financial Services department at (201) 383-1043. This policy covers all emergency and medically necessary services, including employed physician services and behavioral health.
What insurance does Hackensack University Medical Center accept?
Hackensack University Medical Center accepts a wide range of insurance plans, including but not limited to Aetna, Amerigroup, AmeriHealth, Cigna, Clover, Horizon BCBS, and United HC. The hospital is also part of various networks such as Aetna HMO/PPO, Amerihealth PPO/HMO, Cigna HMO/PPO, Horizon HMO/POS/EPO, and United Healthcare Choice Plus/PPO. Patients are advised to verify their eligibility and coverage directly with their insurance provider, as insurance agreements may change.
What awards or recognition has Hackensack University Medical Center received?
Hackensack University Medical Center, located in Hackensack, New Jersey, has been awarded nearly $1 million in grants by the New Jersey Health Foundation to support research in areas such as cancer, infectious disease, community health, education, diabetes, and rheumatology. It stands out as the only hospital in New Jersey to have both its adult and children's hospitals ranked #1, according to U.S. News & World Report, 2023-24. Furthermore, it is nationally-ranked in six specialties.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.